Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma
Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18+
SponsorSun Yat-sen University
About this trial
To evaluate the safety of adebrelimab combined with SHR2554 in the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) and NK/T-cell lymphoma (NKTCL), to determine the recommended Phase 2 dose (RP2D) of the combination regimen, and to assess preliminary efficacy.
Eligibility criteria
Qualifiers
Age ≥18 years old,regardless of gender;
Peripheral T-cell lymphoma, not otherwise specified (PTCL, NOS);
Systemic anaplastic large cell lymphoma (ALK+ and ALK-);
Follicular helper T (TFH) cell lymphoma of lymph nodes, including angioimmunoblastic, follicular, NOS;
Disqualifiers
Pregnant or lactating women;
Patients with hemophagocytic lymphohistiocytosis;
Primary central nervous system (CNS) lymphoma or secondary CNS involvement.
History of allogeneic organ transplantation;
Trial design
Treatments tested in this trial
- Adebrelimab & SHR2554
Treatment groups
40 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov